Allergy Therapeutics PLC (STU:HHU)

€ 0.062 0.0005 (0.81%) Market Cap: 352.82 Mil Enterprise Value: 374.99 Mil PE Ratio: 0 PB Ratio: 62.50 GF Score: 0/100

Full Year 2022 Allergy Therapeutics PLC Earnings Call Transcript
Sep 29, 2022

€0.192 (-0.52%)

Earnings
Q2 2022 Allergy Therapeutics PLC Earnings Call Transcript
Mar 10, 2022

€0.242

Earnings
Q4 2021 Allergy Therapeutics PLC Earnings Call Transcript
Mar 03, 2022

€0.236 (+0.85%)

Earnings
Preliminary Full Year 2021 Allergy Therapeutics PLC Earnings Call Transcript
Sep 23, 2021

€0.426 (-2.74%)

Earnings
Allergy Therapeutics PLC VLP Peanut - a Next Generation Peanut Allergy Immunotherapy Call Transcript
Sep 17, 2021
Half Year 2021 Allergy Therapeutics PLC Earnings Call Transcript
Mar 03, 2021

€0.23 (+9.52%)

Earnings
Allergy Therapeutics PLC Annual Shareholders Meeting Transcript
Dec 08, 2020
Allergy Therapeutics plc - Special Call Transcript
Sep 23, 2020
Half Year 2020 Allergy Therapeutics PLC Earnings Call Transcript
Mar 04, 2020

Earnings
Full Year 2019 Allergy Therapeutics PLC Earnings Call Transcript
Sep 25, 2019

Earnings

Allergy Therapeutics PLC VLP Peanut - a Next Generation Peanut Allergy Immunotherapy Call Transcript

Sep 17, 2021 / 01:00PM GMT

Release Date Price: €0.39

Transcript

Operator

Good day ladies and gentlemen. Welcome to Allergy Therapeutics KOL webinar on VLP Peanut, a new generation peanut allergy immunotherapy. (Operator Instructions)

I will now hand over to the CEO of Allergy Therapeutics Manuel Llobet to open the presentation. Please go ahead.

Manuel Llobet

Allergy Therapeutics plc - CEO & Executive Director

Hello, everybody. Good afternoon. Thank you very much for attending our key opinion leaders event on peanut allergy. I hope you find it interesting and we are very pleased to have you with us today.

When we started our peanut vaccine back in 2016, we saw an opportunity to make a big difference in the food allergy area. Though there were already 2 product candidates in development, there was still a big unmet need even if these candidates were going to succeed. Both were long-term treatments with predictable low compliance and most importantly would not have a disease-modifying effect. We were narrowing the same type of opportunity we saw in the allergic rhinitis field where we introduced the Pollinex

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.